PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-8.26%
Cash & equivalents declining -8.26% while TRAW's grows 81979.44%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-8.26%
Below half of TRAW's 81979.44%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.17%
Below half of TRAW's 81412.52%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-11.00%
Below half TRAW's 88788.89%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.61%
Higher Long-Term Investments Growth compared to TRAW's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.27%
Below half of TRAW's 121639.13%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-8.20%
Below half of TRAW's 81849.33%. Michael Burry sees a potential red flag for stagnation or capital shortage.
18.31%
Less than half of TRAW's 62060.40%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
16.93%
Less than half of TRAW's 70585.51%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.43%
Less than half of TRAW's 200.53%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
2.45%
Less than half of TRAW's 56242.34%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-1.76%
Below half TRAW's -100045.78%. Michael Burry suspects major net losses or high dividends vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-26.00%
Below half TRAW's 137600.00%. Michael Burry sees potential underperformance in building shareholder capital.
-8.20%
Below half TRAW's 81849.33%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
0.61%
Higher Total Investments Growth compared to TRAW's zero value, indicating better performance.
-9.98%
Higher Total Debt Growth compared to TRAW's zero value, indicating worse performance.
8.22%
Less than half of TRAW's -81979.44%. David Dodd sees better deleveraging or stronger cash buildup than competitor.